News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Ipsen Aims To Raise €400 Million In IPO
November 23, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ipsen, the French pharmaceuticals company, yesterday unveiled plans to raise about €400m ($470m) in an initial public offering, which would reduce the stake of the family of founder Henri Beaufour and raise funds for research.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Mergers & acquisitions
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
November 16, 2026
·
1 min read
·
Annalee Armstrong
Business
Their loss, our gain? Canada makes its case to Europe amid U.S. instability
November 16, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Funding
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
November 16, 2026
·
1 min read
·
Gabrielle Masson
Manufacturing
PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
November 13, 2026
·
2 min read
·
Nick Paul Taylor